Bessemer Group Inc. lifted its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 9.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,632,988 shares of the exchange traded fund’s stock after purchasing an additional 138,322 shares during the period. Bessemer Group Inc. owned about 2.69% of SPDR S&P Biotech ETF worth $163,624,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in the company. Capital A Wealth Management LLC bought a new stake in SPDR S&P Biotech ETF in the second quarter valued at $26,000. Johnson Financial Group Inc. purchased a new stake in shares of SPDR S&P Biotech ETF in the 2nd quarter worth about $31,000. Twin Peaks Wealth Advisors LLC bought a new stake in shares of SPDR S&P Biotech ETF during the 2nd quarter valued at about $32,000. Davis Capital Management purchased a new position in shares of SPDR S&P Biotech ETF during the third quarter valued at about $35,000. Finally, Halbert Hargrove Global Advisors LLC purchased a new position in shares of SPDR S&P Biotech ETF during the third quarter valued at about $40,000.
SPDR S&P Biotech ETF Price Performance
Shares of XBI opened at $125.29 on Thursday. The company has a 50-day simple moving average of $124.11 and a two-hundred day simple moving average of $108.08. The firm has a market capitalization of $8.37 billion, a PE ratio of 11.47 and a beta of 0.93. SPDR S&P Biotech ETF has a one year low of $66.66 and a one year high of $132.09.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- The day the gold market broke
- Buy this Gold Stock Before May 2026
- Trump Planning to Use Public Law 63-43: Prepare Now
- Forget AI, This Will Be the Next Big Tech Breakthrough
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
